The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil

Pathologie Biologie

Volumn 57, Issue 6, 2009, Pages 470-476

  Ben Fredj, R ^a   Gross, E ^b   Ben Ahmed, S ^c   Hassine, H ^a   Saguem, S ^a  

^a UNIVERSITY OF SOUSSE   (Tunisia)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c FARHAT HACHED HOSPITAL   (Tunisia)

Author keywords

5 Fluorouracil; DPD deficiency; HPLC method; Pharmacogenetic analysis; Plasmatic dihydrouracil to uracil ratio

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DIHYDROURACIL; DNA; FLUOROURACIL; URACIL;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENZYME DEFICIENCY; FEMALE; FEVER; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LEUKOPENIA; MALE; MEDICAL ASSESSMENT; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RADIATION DETECTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STOMATITIS; ULTRAVIOLET RADIATION; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL NEOPLASMS; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DIHYDROURACIL DEHYDROGENASE (NADP); DNA; FEMALE; FLUOROURACIL; GENETIC TESTING; HALF-LIFE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; SPECTROPHOTOMETRY, ULTRAVIOLET; URACIL;

EID: 69649088627     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2008.05.001     Document Type: Article

References (32)

1. Van Kuilenburg A.B.P., Klumpen H.J., Westermann A.M., Zoetekouw L., Van Lenthe H., Bakker P.J.M., et al. Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin. Eur J Cancer 43 (2007) 459-465
2. Van Kuilenburg A.B.P. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40 (2004) 939-950
3. Heggie G.D., Sommadossi J.P., Cross D.S., Huster W.J., and Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47 (1987) 2203-2206
4. Milano G.A., Etienne M.C., Pierrefite V., Barberi-Heyob M., Deporte-Fety R., and Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79 (1999) 627-630
5. Van Kuilenburg A.B.P., Haasjes J., Richel D.J., Zoetekouw L., Van Lenthe H., De Abrau R.A., et al. Clinical implication of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil- associated toxicity: identification of new mutation in the DPD gene. Clin Cancer Res 6 (2000) 4705-4712
6. Johnson M.R., and Diasio R.B. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 41 (2001) 151-157
7. Jane L.Y., and Howard L.M. Should DPD analysis be required prior to prescribing fluoropyrimidines?. Eur J Cancer 43 (2007) 1011-1016
8. Johnson M.R., Yan J., Shao L., Albin N., and Diasio R.B. Semi automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluoruracil toxicity. J Chromatogr 696 (1997) 183-191
9. Van Kuilenburg A.B.P., Van Lenthe H., and Van Gennip A. Activity of pyrimidine degradation enzyme in normal tissues. Nucleosides Nucleotides Nucleic Acids 25 (2006) 1211-1214
10. Morel A., Boisdron Celle M., Fey L., Lainé-Cessac P., and Gamelin E. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin Biochem 40 (2007) 11-17
11. Van Kuilenburg A.B.P., Meinsma R., Zoetekouw L., and Van Gennip A.H. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS 14 + 1 > A mutation. Int J Cancer 101 (2002) 253-258
12. Van Kuilenburg A.B.P., Vreken P., Abeling N.G.G.M., Bakker H.D., Meinsma R., Van Lenthe H., et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 104 (1999) 1-9
13. Wei X., McLeod H.L., Murrough J.M.C., Gonzalez F.J., and Salguero P.F. Molecular basis of the human dihydropyrimidine dehydropyrimidine deficiency and 5-Fluorouracil toxicity. J Clin Invest 3 (1996) 610-615
14. Gamelin E., Boisdron-Celle M., Guérin-Meyer V., Delva A., Lortholary A., Genevieve F.J., et al. Correlation between uracil and dihydrouracile plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancers: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17 (1999) 1105-1110
15. Jiang H., Lu J., and Ji J. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol 141 (2004) 616-623
16. Gamelin E., Boisdron-Celle M., Larra F., and Robert J. A simple chromatographic method for the analysis of pyrimidines and their dihydrogenated metabolites. J Liq Chromatogr Related Technol 20 (1997) 3155-3172
17. Deporte R., Amiand M., Moreau A., Charbonnel C., and Campion L. High-performance liquid chromatography assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma. J Chromatogr B 834 (2006) 170-177
18. Gross E., Seck K., Neubauer S., Hellebrand H., Ratanaphan A., Lutz V., et al. High- throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro) pyrimidine catabolism. Int J Oncol 22 (2003) 325-332
19. Jones A.C., Austin J., Hansen N., Hoogendoorn B., Oefner P., Cheadle J.P., et al. Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis. Clin Chem 45 (1999) 1133-1140
20. Grem J.L. Screening for dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 11 (2005) 5067-5068
21. Boisdron-Celle M., Remaud G., Traore S., Poirier A.L., Gamelin L., Morel A., et al. 5-fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249 (2007) 271-282
22. Barrat Petit M.A., Naulin Ifi C., Mahler P., and Milano G. Dihydropyrimidine déshydrogénase (DPD) : rythme et conséquences. Pathol Biol 53 (2005) 261-264
23. Zhang X., Soong R., Wang K., Li L., Davie J.R., Guarcello J.R., et al. Suppression of the DPYD expression in RKO cells via DNA methylation in the regulatory region of the promoter: a potentially important epigenetic mechanism regulating DPYD expression. Cell Biol 85 (2007) 337-346
24. Fujiwara H., Terashima M., Irinoda T., Takagane A., Abe K., Kashiwaba M., et al. Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR. Jpn J Cancer Res 93 (2002) 1342-1350
25. Noguchi T., Tanimoto K., Shimokuni T., Ukon K., Tsujimoto H., Fukushima M., et al. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 10 (2004) 7100-7107
26. Zhang X., Li L., Fourie J., R.Davie J., Guarcello V., and Diasio R.B. The role of Sp1 and Sp3 in the constitutive DPYD gene expression. Biochem Biophys Acta 1756 (2006) 247-256
27. Ciccolini J., Mercier C., Dahan L., Evrard A., Boyer J.C., Richard K.J., et al. Toxic death case after capecitabine + oxaliplatine (Xelox) administration: probable implication of dehydropyrimidine dehydrogenase deficiency. Cancer Chemother Pharmacol 58 (2006) 272-275
28. Ben Fredj R., Gross E., Chouchen L., B'chir F., Ben Ahmed S., Neubauer S., et al. Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population. C R Biol 330 (2007) 764-769
29. Ridge S.A., Sludden J., Brown O., Robertson L., Wei X., Sapone A., et al. Dihydropyrimidine dehydrogenase in Caucasians subjects. Br J Clin Pharmacol 46 (1998) 151-156
30. Mattison L.K., Johnson M.R., and Diasio R.B. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics 12 (2002) 133-144
31. Diasio R.B. Dihydropyrimidine dehydrogenase (DPD) deficiency: a 5-fluorouracil-associated pharmacogenomic syndrome. Horiz Cancer Ther 4 (2003) 9-21
32. Johnson M.R., Wang K., and Diasio R.B. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 8 (2002) 768-774